Globally, more than 100 key companies are working in the atopic dermatitis pipeline landscape

DelveInsight’s “Atopic Dermatitis Pipeline Insight, 2022” report provides comprehensive insights on 100+ companies and 100+ drugs in development in the atopic dermatitis pipeline landscape. It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

The Atopic Dermatitis Pipeline report also provides the analysis of inactive products (dormant and terminated) along with the reasons for dormancy and discontinuation if applicable. This report provides detailed pipeline asset profiles and comparative analysis of clinical and non-clinical stage products.

Overview of Atopic Dermatitis

Atopic dermatitis, often called eczema, is a chronic (long-lasting) disease that causes inflammation, redness and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can contract the disease. Atopic dermatitis is not contagious, so it cannot be passed from person to person. Atopic dermatitis causes extreme itching of the skin. Scratching leads to more redness, swelling, cracking, clear “weeping” fluid, crusting and flaking.

Download Sample PDF Report- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

Atopic Dermatitis Pipeline Analysis

The report provides information on:

  • The report provides detailed insights into the companies that are developing therapies in the atopic dermatitis
  • It accesses the various therapeutic candidates segmented in early, intermediate and advanced stages of development to atopic dermatitis
  • atopic dermatitis key companies involved in the development of targeted therapies with respective active and inactive (dormant or discontinued) projects.
  • atopic dermatitis Drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-university collaborations), license agreement and funding details for the future advancement of the atopic dermatitis

The report is constructed using data and information from researchers’ proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, presentations to investors and press releases presented from corporate/academic websites and industry-specific third-party sources. etc

Emerging drugs for atopic dermatitis

  • Amlitelimab: Kymab
  • BX 005: BiomX
  • LP 0145: LEO Pharma

Atopic Dermatitis Therapeutic Pipeline Analysis

Approx. Over 100 key companies developing therapies for atopic dermatitis. Among the companies whose drug candidates against atopic dermatitis are at the most advanced stage, that is to say in phase II, are LEO Pharma.

Atopic Dermatitis Pipeline Phases

The DelveInsight report covers approximately 100+ products under different phases of clinical development such as

  • Late-stage products (Phase III)
  • Intermediate products (Phase II)
  • Product at an early stage (Phase I) as well as details of
  • Candidates in the preclinical and discovery phase
  • Abandoned and Inactive Candidates

Atopic Dermatitis Pipeline Companies

  • Kymab
  • BiomX
  • LEO Pharma
  • GlaxoSmithKline
  • Arjil Pharmaceuticals
  • SCM Life Sciences
  • Sun Pharmaceutical Industries Limited
  • Brickell Biotech Inc.
  • Dermis
  • Astra Zeneca
  • Kyowa Kirin
  • UCB Biopharma
  • Arcutis Biotherapeutics, and many more

Atopic Dermatitis Pipeline Molecule Type

The products have been categorized under different types of molecules such as

  • Oligonucleotide
  • peptide
  • small molecule

Atopic Dermatitis Pipeline Report Highlights

Companies and academics are working to assess challenges and seek out opportunities that can influence atopic dermatitis R&D. Therapies in development are focused on new approaches to treat/improve diffuse large B-cell lymphoma.

Emerging Drugs for Atopic Dermatitis Chapters

This segment of the Atopic Dermatitis report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Request sample PDF report- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

Contents

  1. Introduction
  2. Summary
  3. Atopic dermatitis: overview
  4. Pipeline therapeutics
  5. Therapeutic assessment
  6. Atopic Dermatitis – Analytical Perspective from DelveInsight
  7. Late-stage products (Phase III)
  8. Drug name: Company name
  9. Mid-term products (Phase II)
  10. Amlitelimab: Kymab
  11. Early Stage Products (Phase I/II)
  12. Drug name: Company name
  13. Products in the preclinical and discovery phase
  14. Drug name: Company name
  15. Inactive products
  16. Key atopic dermatitis companies
  17. Key Atopic Dermatitis Products
  18. Atopic Dermatitis – Unmet Needs
  19. Atopic Dermatitis – Market Drivers and Barriers
  20. Atopic Dermatitis – Future Perspectives and Conclusion
  21. Opinions of atopic dermatitis analysts
  22. Key atopic dermatitis companies
  23. Annex

Do you have any questions about the report? If yes, click here- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

Media Contact
Company Name: DelveInsight
Contact person: Yash
E-mail: Send an email
Call: +919650213330
Address:304 S. Jones Boulevard #2432
Town: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Comments are closed.